MX2022001803A - [1,2,4]triazolo[1,5-c]quinazolin-5-aminas. - Google Patents

[1,2,4]triazolo[1,5-c]quinazolin-5-aminas.

Info

Publication number
MX2022001803A
MX2022001803A MX2022001803A MX2022001803A MX2022001803A MX 2022001803 A MX2022001803 A MX 2022001803A MX 2022001803 A MX2022001803 A MX 2022001803A MX 2022001803 A MX2022001803 A MX 2022001803A MX 2022001803 A MX2022001803 A MX 2022001803A
Authority
MX
Mexico
Prior art keywords
compounds
quinazolin
triazolo
preparing
pharmaceutical compositions
Prior art date
Application number
MX2022001803A
Other languages
English (en)
Inventor
Norbert Schmees
Bernd Buchmann
Ludwig Zorn
Michael Platten
Lars Röse
Benjamin Bader
Julien Lefranc
Simon Anthony Herbert
Ilona Gutcher
Ulrich Bothe
Judith Günther
Christina Kober
Robin Michael Meier
Detlef Stöckigt
Mátyás Gorjánácz
Stephan Böhme
Daniel Baumann
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of MX2022001803A publication Critical patent/MX2022001803A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Abstract

La presente invención comprende compuestos de [1,2,4]triazolo[1,5-c]quinazolin-5-amina de la fórmula general (I): (ver Fórmula) en donde R1, R2, R3, R4, R5, R6, R7 y R8 son como se definen en la presente, métodos para la preparación de dichos compuestos, compuestos intermedios útiles para la preparación de dichos compuestos, composiciones farmacéuticas y combinaciones que comprenden dichos compuestos y el uso de dichos compuestos para la elaboración de composiciones farmacéuticas para el tratamiento o la profilaxis de enfermedades, en especial de cáncer o afecciones con respuestas inmunes desreguladas u otros trastornos asociados con la señalización anormal de AHR, como un único agente o en combinación con otros ingredientes activos.
MX2022001803A 2019-08-12 2020-08-10 [1,2,4]triazolo[1,5-c]quinazolin-5-aminas. MX2022001803A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19191299 2019-08-12
EP20167707 2020-04-02
PCT/EP2020/072377 WO2021028382A1 (en) 2019-08-12 2020-08-10 [1,2,4]triazolo[1,5-c]quinazolin-5-amines

Publications (1)

Publication Number Publication Date
MX2022001803A true MX2022001803A (es) 2022-03-11

Family

ID=72243077

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001803A MX2022001803A (es) 2019-08-12 2020-08-10 [1,2,4]triazolo[1,5-c]quinazolin-5-aminas.

Country Status (19)

Country Link
US (1) US20230113037A1 (es)
EP (1) EP4013508A1 (es)
JP (1) JP2022544952A (es)
KR (1) KR20220045978A (es)
CN (1) CN114466850A (es)
AU (1) AU2020328154A1 (es)
BR (1) BR112022001628A2 (es)
CA (1) CA3150544A1 (es)
CO (1) CO2022001257A2 (es)
CR (1) CR20220064A (es)
DO (1) DOP2022000031A (es)
EC (1) ECSP22009803A (es)
GE (1) GEP20247611B (es)
IL (1) IL290445A (es)
JO (1) JOP20220034A1 (es)
MX (1) MX2022001803A (es)
PE (1) PE20220967A1 (es)
TW (1) TW202126655A (es)
WO (1) WO2021028382A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4139287A1 (en) 2020-04-24 2023-03-01 Bayer Aktiengesellschaft Substituted aminothiazoles as dgkzeta inhibitors for immune activation
WO2022049253A1 (en) * 2020-09-07 2022-03-10 Bayer Aktiengesellschaft Substituted n-heteroaryl-n-pyridinylacetamides as p2x4 modulators
CN114181212B (zh) * 2020-09-15 2023-06-06 山东轩竹医药科技有限公司 哒嗪酮类AhR抑制剂
CN114621236A (zh) * 2022-04-25 2022-06-14 河南湾流生物科技有限公司 一种喹啉类饲料添加剂的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6358964B1 (en) * 2000-07-26 2002-03-19 King Pharmaceuticals Research And Development, Inc. Adenosine, A3 receptor modulators
WO2007040565A2 (en) 2004-11-22 2007-04-12 King Pharmaceuticals Research & Development, Inc. Enhancing treatment of cancer and hif-1 mediated disoders with adenosine a3 receptor antagonists
PE20100362A1 (es) * 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
WO2012015914A2 (en) * 2010-07-27 2012-02-02 Trustees Of Boston University Aryl hydrocarbon receptor (ahr) modifiers as novel cancer therapeutics
US20220017524A1 (en) * 2018-11-14 2022-01-20 The Broad Institute, Inc. Aryl hydrocarbon receptor (ahr) activator compounds as cancer therapeutics

Also Published As

Publication number Publication date
TW202126655A (zh) 2021-07-16
DOP2022000031A (es) 2022-03-15
AU2020328154A1 (en) 2022-03-03
IL290445A (en) 2022-04-01
JOP20220034A1 (ar) 2023-01-30
JP2022544952A (ja) 2022-10-24
CO2022001257A2 (es) 2022-03-08
GEP20247611B (en) 2024-03-11
PE20220967A1 (es) 2022-06-10
KR20220045978A (ko) 2022-04-13
WO2021028382A1 (en) 2021-02-18
CN114466850A (zh) 2022-05-10
BR112022001628A2 (pt) 2022-06-21
EP4013508A1 (en) 2022-06-22
ECSP22009803A (es) 2022-03-31
US20230113037A1 (en) 2023-04-13
CA3150544A1 (en) 2021-02-18
CR20220064A (es) 2022-05-04

Similar Documents

Publication Publication Date Title
PH12018502472A1 (en) 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides
PH12019501846A1 (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
MX2022001803A (es) [1,2,4]triazolo[1,5-c]quinazolin-5-aminas.
PH12018550173A1 (en) Pyrazolopyrimidine derivatives
MX2022006466A (es) Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activacion inmune.
PH12020500257A1 (en) Quinoline derivatives for treating infections with helminths
PH12019502851A1 (en) New azaquinoline derivatives
WO2018077944A3 (en) 4,5-annulated 1,2,4-triazolones
MX2021004707A (es) Nuevos compuestos antihelminticos.
PH12020551891A1 (en) New quinoline derivatives
WO2020126968A3 (en) Urea derivatives for use against proliferative diseases
WO2017198341A8 (en) MACROCYCLIC INDOLE DERIVATIVES
MX2019012803A (es) Nuevos derivados de pirazol biciclicos.
PH12020500134A1 (en) Dihydrooxadiazinones
SA518400501B1 (ar) مركبات [8- (فنيل سلفونيل)-3، 8-ديازا ثنائي سيكلو [3. 2. 1] أوكتـ-3-يل] ميثانون (1h-1، 2، 3-تريازول-4-يل)
EA201991835A1 (ru) 2-гетероарил-3-оксо-2,3-дигидропиридазин-4-карбоксамиды для лечения злокачественного новообразования